Arrowhead Pharmaceuticals Inc. (ARWR)

28.86
NASDAQ : Health Technology
Prev Close 29.09
Day Low/High 28.32 / 29.53
52 Wk Low/High 10.41 / 36.80
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 2.77B
EPS -0.70
P/E Ratio 64.22
Div & Yield N.A. (N.A)
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Presents New Data On ARC-F12 And ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

Arrowhead Pharmaceuticals Presents New Data On ARC-F12 And ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today delivered oral presentations on ARC-LPA, its preclinical development program targeting lipoprotein (a), for the treatment of cardiovascular disease, and ARC-F12, its...

Interesting ARWR Put And Call Options For January 2019

Interesting ARWR Put And Call Options For January 2019

Investors in Arrowhead Pharmaceuticals Inc saw new options become available today, for the January 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals Presents New Data On ARC-AAT

Arrowhead Pharmaceuticals Presents New Data On ARC-AAT

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) delivered a poster presentation with Phase 1 clinical data and an oral presentation with preclinical data on ARC-AAT, its investigational medicine for the treatment of liver...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Arrowhead Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Arrowhead Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Provides Update On Heparc-2004 Study

Arrowhead Pharmaceuticals Provides Update On Heparc-2004 Study

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is providing an update on its Heparc-2004 clinical study of ARC-520, its therapeutic candidate under clinical investigation for the treatment of chronic hepatitis B virus (HBV)...

Arrowhead Pharmaceuticals To Present At Upcoming Conferences

Arrowhead Pharmaceuticals To Present At Upcoming Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events: The 25 th Annual Credit Suisse Healthcare Conference - Scottsdale, AZ, November 6-8, 2016 ...

Relative Strength Alert For Arrowhead Pharmaceuticals

Relative Strength Alert For Arrowhead Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Arrowhead Pharmaceuticals To Present Data On ARC-AAT At The Liver Meeting®

Arrowhead Pharmaceuticals To Present Data On ARC-AAT At The Liver Meeting®

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will make two presentations on ARC-AAT, the company's investigational medicine for the treatment of liver disease associated with alpha-1 antitrypsin...

Arrowhead And Spring Bank Announce Clinical Collaboration For ARC-520 And SB 9200 In Chronic Hepatitis B

Arrowhead And Spring Bank Announce Clinical Collaboration For ARC-520 And SB 9200 In Chronic Hepatitis B

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Spring Bank Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships

Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships

Amgen (AMGN) is partnering with Arrowhead Pharmaceuticals (ARWR) to develop two cardiovascular disease treatments using its RNAi therapy.

First Week of November 18th Options Trading For Arrowhead Pharmaceuticals (ARWR)

First Week of November 18th Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Arrowhead Pharmaceuticals Initiates Phase 2 Study Of ARC-AAT

Arrowhead Pharmaceuticals Initiates Phase 2 Study Of ARC-AAT

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 2 clinical study of ARC-AAT, an investigational RNAi-based medicine for the treatment of liver disease associated with alpha-1...

Arrowhead Pharmaceuticals To Present At Upcoming September Conferences

Arrowhead Pharmaceuticals To Present At Upcoming September Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.

Notable Thursday Option Activity: ARWR, ROST, OUTR

Notable Thursday Option Activity: ARWR, ROST, OUTR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arrowhead Pharmaceuticals Inc , where a total of 3,324 contracts have traded so far, representing approximately 332,400 underlying shares. That amounts to about 61.7% of ARWR's average daily trading volume over the past month of 538,710 shares.

Arrowhead Pharmaceuticals Closes $45 Million Private Offering

Arrowhead Pharmaceuticals Closes $45 Million Private Offering

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW...

Arrowhead Reports Fiscal 2016 Third Quarter Results

Arrowhead Reports Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 third quarter ended June 30, 2016.

Arrowhead Pharmaceuticals Prices $45 Million Private Offering

Arrowhead Pharmaceuticals Prices $45 Million Private Offering

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million.

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, August 9, 2016, at 4:30 p.

Commit To Purchase Arrowhead Pharmaceuticals At $3, Earn 15% Using Options

Commit To Purchase Arrowhead Pharmaceuticals At $3, Earn 15% Using Options

Investors eyeing a purchase of Arrowhead Pharmaceuticals Inc shares, but cautious about paying the going market price of $5.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 45 cents.

Arrowhead Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Arrowhead Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single And Multiple Dose Study Of Hepatitis B Candidate ARC-521

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single And Multiple Dose Study Of Hepatitis B Candidate ARC-521

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV)...

Arrowhead Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

Arrowhead Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.

Arrowhead Reports Fiscal 2016 Second Quarter Results

Arrowhead Reports Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 second quarter ended March 31, 2016.

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown And Long Duration Of Effect After Subcutaneous Administration

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown And Long Duration Of Effect After Subcutaneous Administration

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease at the...

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, May 10, 2016, at 4:30 p.

TheStreet Quant Rating: C+ (Hold)